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ABSTRACT
Background and aims The role of GATA factors in
cancer has gained increasing attention recently, but the
function of GATA6 in pancreatic ductal adenocarcinoma
(PDAC) is controversial. GATA6 is ampliﬁed in a subset
of tumours and was proposed to be oncogenic, but high
GATA6 levels are found in well-differentiated tumours
and are associated with better patient outcome.
By contrast, a tumour-suppressive function of GATA6
was demonstrated using genetic mouse models. We
aimed at clarifying GATA6 function in PDAC.
Design We combined GATA6 silencing and
overexpression in PDAC cell lines with GATA6 ChIP-Seq
and RNA-Seq data, in order to understand the
mechanism of GATA6 functions. We then conﬁrmed
some of our observations in primary patient samples,
some of which were included in the ESPAC-3
randomised clinical trial for adjuvant therapy.
Results GATA6 inhibits the epithelial–mesenchymal
transition (EMT) in vitro and cell dissemination in vivo.
GATA6 has a unique proepithelial and antimesenchymal
function, and its transcriptional regulation is direct and
implies, indirectly, the regulation of other transcription
factors involved in EMT. GATA6 is lost in tumours, in
association with altered differentiation and the
acquisition of a basal-like molecular phenotype,
consistent with an epithelial-to-epithelial (ET2) transition.
Patients with basal-like GATA6low tumours have a
shorter survival and have a distinctly poor response to
adjuvant 5-ﬂuorouracil (5-FU)/leucovorin. However,
modulation of GATA6 expression in cultured cells does
not directly regulate response to 5-FU.
Conclusions We provide mechanistic insight into
GATA6 tumour-suppressive function, its role as a
regulator of canonical epithelial differentiation, and
propose that loss of GATA6 expression is both prognostic
and predictive of response to adjuvant therapy.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC), the
most common type of pancreatic cancer, has a
dismal prognosis1 2 with a 5-year survival of 25%–
30% after resection and adjuvant chemotherapy
with either gemcitabine or 5-ﬂuorouracil (5-FU)
+leucovorin or gemcitabine.3–7 Most patients
present with advanced disease and are not eligible
Signiﬁcance of this study
What is already known on this subject?
▸ GATA6 maintains the epithelial differentiation in the
mouse pancreas and suppresses mutant KRas-driven
tumourigenesis in the mouse.
▸ Pancreatic tumours of the classical subtype,
characterised by better outcome, have high GATA6
expression.
▸ GATA6 is ampliﬁed in a subset of pancreatic
tumours, and its overexpression increases
proliferation of pancreatic cancer cells in vitro.
▸ Patients with tumours carrying GATA6 ampliﬁcations/
copy number gains survive longer.
What are the new ﬁndings?
▸ GATA6 regulates epithelial–mesenchymal transition
(EMT) in pancreatic cancer cells through a unique
mechanism, both direct and indirect, controlling
both the epithelial and the mesenchymal
transcriptional programmes.
▸ GATA6 suppresses the ectopic expression of a
basal-like molecular phenotype, similar to the one
described in breast and bladder cancer, which is
activated in a subset of GATA6lowtumours.
▸ Patients with basal-like GATA6low tumours show a
worse survival than those with GATA6medium or
GATA6high tumours.
▸ Patients with GATA6low tumours have a worse
outcome when treated with 5-ﬂuorouracil (5-FU)/
leucovorin adjuvant therapy, compared with patients
with GATA6high tumours, while treatment with
gemcitabine has the same effect on both groups
How might it impact on clinical practice in
the foreseeable future?
▸ We ﬁnally provide an explanation to the conundrum
derived from the observation that GATA6 is
ampliﬁed in a subset of tumours; yet, patients with
high GATA6 survive longer.
▸ GATA6 expression could be a marker for patients’
prognosis.
▸ If conﬁrmed in an independent study, our
observation that patients with GATA6low tumours
have a worse outcome when treated with 5-FU/
leucovorin adjuvant therapy could guide the choice
of treatment for patients with pancreatic cancer.
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for surgery. Gemcitabine is the mainstay of therapy for locally
advanced and metastatic disease. Recently, gemcitabine+nab-
paclitaxel and FOLFIRINOX combination chemotherapies
showed a modest improvement in survival of patients with
advanced disease.8 9
Exome/genome sequencing of PDAC has revealed a complex
pattern of genetic alterations, affecting multiple core signalling
pathways.10 The few frequently altered genes (KRAS, CDKN2A,
TP53, SMAD4) have proven difﬁcult to target therapeutically.
The remaining alterations occur in <10% of tumours and,
therefore, are not ideal targets for new therapies. Patient stratiﬁ-
cation for treatment selection is unfeasible because of the scar-
city of pathological/molecular markers that can reliably predict
therapeutic response. The recent report of high hENT-1 tumour
protein levels being associated with response to gemcitabine is
promising, but needs to be replicated in prospective studies.11
The identiﬁcation of new therapeutic targets and markers for
patient stratiﬁcation and targeted treatment are the two
priorities.
Omics technologies provide a new molecular taxonomy of
cancer. In PDAC, few studies have aimed at a molecular-based
classiﬁcation. Collisson et al12 identiﬁed three PDAC subtypes:
classical, exocrine and mesenchymal-like. Classical tumours
showed high GATA6 mRNA expression, and patients had a sig-
niﬁcantly better outcome. Cells with a classical phenotype
showed distinct response to chemotherapy in vitro.12 GATA6
belongs to a family of transcription factors that bind to the (A/
T)GATA(A/G) consensus sequence to activate or repress gene
expression.13 GATA factors are important for cell differenti-
ation, and GATA6 is essential for the maintenance of the exo-
crine pancreas in adult mice.14 An oncogenic role was proposed
for GATA6 in PDAC based on the occurrence of GATA6 gains/
ampliﬁcations in a small proportion of tumours.15 16 However,
high GATA6 copy number is signiﬁcantly associated with a
better outcome in patients with PDAC,17 suggesting that its
function could be more complex than originally proposed. A
tumour-suppressive role of GATA6 has been recently postulated
in PDAC mouse models,18 19 where it regulates differentiation-
related as well as cancer-related transcriptional programmes.
Here, we show that, in human PDAC cells, GATA6 inhibits
de-differentiation and epithelial–mesenchymal transition (EMT),
both directly and indirectly, through a unique mechanism that
involves the regulation of transcription factors, including
FOXA1/2. Consistently, loss of GATA6 in PDAC primary
samples is associated with altered differentiation and shorter
overall patient survival. Finally, the analysis of tumour samples
from the ESPAC-3 randomised adjuvant chemotherapy trial7
shows that low GATA6 expression can predict worse response
to adjuvant 5-FU/leucovorin.
RESULTS
GATA6 maintains the canonical epithelial phenotype
in PDAC cells
To determine the function of GATA6, we analysed its expression
in a panel of PDAC cell lines to select the optimal models for
loss-of-function and gain-of-function analyses (see online sup-
plementary ﬁgure S1). We silenced GATA6 in three PDAC cell
lines, including one with GATA6 ampliﬁcation (A13B),16 using
two different lentiviral-driven shRNAs (ﬁgure A, B and see
online supplementary ﬁgure S2A–C). PaTu8988S cells grew as
compact colonies and, upon GATA6 silencing, acquired a
spindle-like shape and showed increased scattering.
Furthermore, E-cadherin was downregulated and vimentin was
upregulated (ﬁgure 1A, B), all features suggesting an EMT.
Similarly, GATA6-silenced A13B cells showed lower E-cadherin
levels (see online supplementary ﬁgure S2B, S2D) and
GATA6-silenced SK-PC-1 cells showed increased vimentin levels
(see online supplementary ﬁgure S2D). Despite the partially dif-
ferent cell-speciﬁc effects of GATA6 silencing (likely dependent
on the extent of downregulation and the genetic background),
we observed a common convergence towards EMT.
Consistently, GATA6 overexpression in L3.6pl PDAC cells—dis-
playing a looser growth pattern—resulted in the formation of
compact colonies, reduced scattering, upregulated E-cadherin
expression and downregulated vimentin (ﬁgure 1C–D and see
online supplementary ﬁgure S2F). These ﬁndings support a
mesenchymal–epithelial transition (MET) and demonstrate that
GATA6 maintains the canonical epithelial phenotype in PDAC
cells.
GATA6 inhibits invasion in vitro and cell dissemination
in vivo
EMT plays an important role in tumour progression and spread-
ing20 21 and is associated with the outcome in patients with
PDAC.22 Consistently, GATA6-silenced PaTu8988S and SK-PC-1
cells displayed increased capacity to invade in vitro (ﬁgure 2A
and see online supplementary ﬁgure S2E), while invasiveness
was reduced in L3.6pl cells overexpressing GATA6 (ﬁgure 2B).
To assess the contribution of GATA6 to tumour cell dissemin-
ation, we injected GATA6-silenced PaTu8988S and GATA6-over-
expressing L3.6pl cells—and the respective control cells—into
the spleen of athymic Foxn1nu mice and measured human gene
expression in the liver by qPCR, an estimate of dissemination.
GATA6 silencing in PaTu8988S cells signiﬁcantly increased
their capacity to reach the liver (p=0.048), while GATA6 over-
expression in L3.6pl cells had the opposite effect (p=0.032)
(ﬁgure 2C).
These data suggest that, through the regulation of EMT/MET,
GATA6 might inhibit the acquisition of metastatic potential in
PDAC cells. Furthermore, GATA6 was expressed at comparable
levels in primary tumours (n=145) and adjacent normal pan-
creas (n=46) included in a recently published dataset,23 while it
was signiﬁcantly reduced in metastases (n=61) (p<0.001, see
online supplementary ﬁgure S3), consistent with an antimeta-
static role for GATA6 in patients.
GATA6 blocks EMT directly and indirectly
EMT is mainly controlled by SNAI, ZEB and TWIST transcrip-
tion factors, repressing E-cadherin expression and epithelial dif-
ferentiation,20 while few positive regulators of the epithelial
programme are known.
E-cadherin mRNA was reduced in all GATA6-silenced cells
analysed (ﬁgure 3A) and upregulated in GATA6-overexpressing
L3.6pl cells (ﬁgure 3B). Furthermore, mRNA levels of SNAI2,
ZEB1 and TWIST1 were upregulated in GATA6-silenced
PaTu8988S cells, as were the levels of the mesenchymal marker
vimentin (ﬁgure 3C). Accordingly, SNAI1 and vimentin mRNA
levels were reduced in GATA6-overexpressing L3.6pl cells
(ﬁgure 3B). These data suggest that GATA6 can regulate
EMT-MET through the canonical pathway involving
EMT-inducing transcription factors (EMT-TFs). The
GATA6-dependent changes in EMT-TFs levels varied among dif-
ferent cell lines, suggesting convergence in the regulation of
EMT-MET.
To further unravel how GATA6 regulates EMT, we deter-
mined its genome-wide distribution in PaTu8988S cells using
ChIP-Seq. GATA6 occupied 26 248 genomic regions
(FDR<0.01, see online supplementary dataset S1). The
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canonical GATAA sequence was the most enriched motif in the
sequenced tags (see online supplementary ﬁgure S4A, E-value:
3.8e-350). GATA6 peaks were preferentially found (40%)
within 1 kb from the transcription start site (TSS) of coding
genes (see online supplementary ﬁgure S4B). ChIP-qPCR con-
ﬁrmed the ChIP-Seq results for a subset of genes (see online
supplementary ﬁgure S4C).
A manual EMT-targeted analysis revealed two GATA6 peaks
in the E-cadherin locus (see online supplementary ﬁgure S4D).
One of them included the TSS and contained a non-canonical
GATC sequence to which GATA3 binds in breast cancer cells.24
We conﬁrmed GATA6 binding on this sequence and on the TSS
(ﬁgure 3D). Wild-type GATA6—but not a DNA-binding
mutant17—enhanced the activity of an E-cadherin promoter–
reporter construct including the TSS (ﬁgure 3E), indicating
direct transcriptional activation. Another peak is close to four
canonical GATAA motifs; binding in the proximity of the ﬁrst
of them was conﬁrmed by ChIP-qPCR (ﬁgure 3D). GATA6 also
bound the promoter of multiple epithelial genes, including pro-
tocadherins, tight junction components (CLDN1, CLDN4,
CLDN7, OCLN, TJP1, TJP2, TJP3), desmosomal proteins
(DSC2, DSC3, DSG2), integrins, and keratins. We observed
GATA6 binding to the promoter of SNAI1 and ZEB1, and to
the second intron of ZEB2 (conﬁrmed by ChIP-qPCR; ﬁgure 3F
and see online supplementary ﬁgure S4D). GATA6 was also
found in the promoter of VIM (coding for vimentin) and other
mesenchymal genes (ﬁgure 3F and see online supplementary
ﬁgure S4D). Gene-enrichment and functional annotation ana-
lysis (DAVID suite)25 on 5643 GATA6 peaks located <1 kb
from a TSS and with FDR<0.1% (see online supplementary
table S1) revealed enrichment of ‘focal adhesion’, ‘tight junc-
tion’, and ‘regulation of actin cytoskeleton’ pathways. The
TGFβ and ERBB pathways, involved in EMT and in PDAC,10
were also enriched. These results indicate that GATA6 has a
broad direct proepithelial function and concomitantly inhibits
the mesenchymal programme.
GATA6 regulates the E-cadherin inducers FOXA1 and FOXA2
Among the few known E-cadherin transcriptional activators are
FOXA1 and FOXA2,26 two important regulators of pancreatic
development.27 Prominent GATA6 peaks in FOXA1 and FOXA2
suggested strong binding (ﬁgure 4A), conﬁrmed at their TSS by
Figure 1 GATA6 is required for the maintenance of the epithelial phenotype of pancreatic ductal adenocarcinoma (PDAC) cells. (A) Top: phase
contrast microphotographs of PaTu8988S cells infected with either shCtrl or two different GATA6-targeting shRNAs (shG6-1 and shG6-2). Higher
magniﬁcation of the highlighted region is shown in the inset. Bottom: expression of E-cadherin and vimentin detected by immunoﬂuorescence.
Nuclear counterstaining with diamidino-2-phenylindole (DAPI) is shown separately. Scale bars: 50 μm. (B) Expression of GATA6, KRT5, KRT14,
E-cadherin and vimentin, detected by western blotting, in total lysates from PaTu8988S cells infected with the indicated constructs. Vinculin was
used as a loading control. (C) Left: L3.6pl cells infected with either an empty vector (Ctrl) or a GATA6-overexpressing vector (G6). Right: expression
of E-cadherin, and vimentin detected by immunoﬂuorescence. Nuclear counterstain with DAPI is shown separately. Scale bars: 50 μm. (D) Expression
of GATA6, E-cadherin and vimentin detected by western blotting in total lysates from L3.6pl cells infected with the indicated constructs. Vinculin
was used as a loading control.
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ChIP-qPCR (ﬁgure 4B). FOXA1/2 mRNAs were upregulated in
GATA6-overexpressing L3.6 cells (ﬁgure 4C) and repressed in
GATA6-silenced PaTu8988S and SK-PC-1 cells (ﬁgure 4D);
FOXA1/2 proteins were reduced in GATA6-silenced PaTu8988S
cells (ﬁgure 4E). Furthermore, wild-type GATA6—but not the
mutant—activated FOXA1 and FOXA2 promoter–reporter con-
structs (ﬁgure 4F). Interestingly, the FOXA DNA binding
sequence was the second most enriched motif in the GATA6
ChIP-Seq (see online supplementary ﬁgure S4A), and we con-
ﬁrmed FOXA2 binding to a subset of GATA6 targets including
both activated and repressed genes (see online supplementary
ﬁgure S4E). Altogether, these data indicate that GATA6 activates
transcription of E-cadherin, and possibly other targets, also
indirectly through the induction of FOXA1 and FOXA2. GATA6
and FOXA1/2 thus cooperate in their proepithelial function. To
assess the contribution of FOXA1/2 to GATA6-dependent func-
tions, we silenced them individually in GATA6-overexpressing
L3.6pl cells, but massive cell death precluded further analyses
(not shown).
GATA6 is lost in human PDAC, in association with loss of
epithelial differentiation
We analysed GATA6, E-cadherin and FOXA2 by IHC in
tumours (n=25) using 4 mm core tissue microarrays (TMA),
allowing for detection of intratumour heterogeneity. GATA6
was lost broadly or focally in 4 (16%) and 12 cases (48%),
respectively. E-cadherin was consistently low/mislocalised in all
the GATA6neg tumours and in areas of focal GATA6 loss.
Likewise, FOXA2 was low in the GATA6neg regions, supporting
the relevance of the GATA6–FOXA2–E-cadherin axis in primary
PDAC (ﬁgure 5A). In a meta-dataset of four published PDAC
gene expression studies (META, n=108),28–31 we conﬁrmed a
positive correlation of GATA6, FOXA2 and E-cadherin mRNA
levels (p<0.001 for all comparisons; ﬁgure 5B). Similar correla-
tions were observed in an independent series (Mofﬁtt, see
online supplementary ﬁgure S5).23 FOXA1 expression did not
correlate with GATA6, FOXA2 or E-cadherin (data not shown),
suggesting that FOXA2 is the main GATA6 partner in PDAC.
Our observations suggest a tumour-suppressive role of GATA6
in human PDAC, concordant with our ﬁndings for mouse
PDAC.18 This notion is at odds with the occurrence of GATA6
ampliﬁcations in 10%–20% of PDACs,15 16 32 which led to the
proposal that it is a PDAC oncogene. To solve this conundrum,
we reanalysed GATA6 gene copy number changes in three
PDAC series (CNV, see online supplementary table S2):32 33 34
13/117 (11%) tumours showed ampliﬁcations, but losses
occurred at a similar rate (17/117, 14.5%) (ﬁgure 5C and see
online supplementary table S2). GATA6 is on 18q11, 28.7 Mb
from SMAD4, which is frequently deleted in PDAC. GATA6 and
SMAD4 were lost concomitantly in 11/17 cases and separately
in 6/17 cases, suggesting that an independent selective pressure
acts against GATA6 in some PDACs (ﬁgure 5C and see online
supplementary table S2). GATA6 losses were conﬁrmed in a
subset (9/100) of PDAC recently reported by the Australian
Pancreas Cancer Initiative.35
Low GATA6 identiﬁes a PDAC subtype with
basal-like features
To gain insight into GATA6 function in PDACs, we compared
the transcriptome of tumours belonging to the highest and
lowest GATA6 expression quartiles in the PDAC meta-dataset
(GATA6high and GATA6low, n=27 for each group) and identiﬁed
495 genes upregulated or downregulated in GATA6low versus
GATA6high with FDR<0.01 (see online supplementary dataset
S2). Gene sets induced in basal-like (BAS-L) and suppressed in
luminal-like breast cancers were enriched among genes upregu-
lated in GATA6low tumours (see online supplementary table S3
and ﬁgure S6).
Recently, a BAS-L subtype of bladder cancer was described car-
rying similarities with the corresponding breast cancer subtype,
suggesting that poorly differentiated carcinomas of distinct origin
might converge to a similar molecular phenotype. Hierarchical
clustering of the meta-dataset samples according to a bladder
cancer-deﬁned 47-gene signature (BASE47)36 identiﬁed a BAS-L
subgroup of PDAC (see online supplementary ﬁgure S7A).
Basal keratins are expressed in a subset of PDACs but are
undetectable in normal pancreas.12 37 Using the TMAs
described earlier, KRT14 was found in the GATA6neg regions of
7/16 PDACs, while it was absent from GATA6high regions
(ﬁgure 5A). Consistently, GATA6 was signiﬁcantly lower in
Figure 2 GATA6 inhibits invasion in vitro and cell dissemination in vivo. (A) Quantiﬁcation of the in vitro invasiveness of PaTu8988S cells infected
with the indicated constructs, measured as number of invading cells per microscopic ﬁeld (×20 magniﬁcation). Data are mean±SEM of at least three
independent experiments; **p<0.01. (B) Quantiﬁcation of the in vitro invasiveness of L3.6pl cells infected with the indicated constructs. Data are
mean±SEM of at least three independent experiments; **p<0.01. (C) Quantiﬁcation of the metastatic burden in the liver of nude mice after
intrasplenic injection of the indicated cells, measured by qPCR with human-speciﬁc primers detecting HPRT; *p<0.05.
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BAS-L tumours (p<0.001, see online supplementary ﬁgure
S7B), and GATA6-silenced PaTu8988S cells ectopically
expressed the basal keratins KRT5 and KRT14 (ﬁgure 1B).
Furthermore, ChIP-Seq data showed GATA6 binding to the pro-
moter of genes belonging to multiple published basal-related sig-
natures,36 38 39 some of which were also regulated in the
RNA-Seq experiment (see online supplementary dataset S3).
Altogether, these data suggest that GATA6 participates in the
regulation of the BAS-L transcriptional programme and that
basal-like PDACs are GATA6low.
Low GATA6 expression predicts poor survival and distinct
response to adjuvant chemotherapy in patients with PDAC
Patients with BAS-L bladder and breast tumours have worse
outcome and a distinct response to therapy.36 38 39 To assess the
impact of GATA6 loss on patient survival, we analysed a series
of 58 patients from whom xenografts were established and tran-
scriptome data were available. Patients were categorised based
on GATA6 expression values in three groups (<500, 500–1000,
>1000). In this exploratory series, GATA6 levels were not sig-
niﬁcantly associated with the clinical–pathological variables con-
sidered (see online supplementary table S4). The survival of
patients with GATA6medium and GATA6high tumours was similar
(12.7 vs 13.1 months, respectively) and signiﬁcantly longer than
those with GATA6low tumours (4.6 months, p=0.003)
(ﬁgure 6A,B). Low GATA6 expression was associated with sig-
niﬁcantly increased death risk both in the univariate analysis
(HR=5.39, 95% CI 2.3 to 12.9; p<0.001) and in the model
adjusted by age and gender (HR=3.77, 95% CI 1.74 to 8.17;
p=0.001) (table 1).
Figure 3 GATA6-dependent direct and indirect transcriptional regulation of epithelial–mesenchymal transition (EMT). (A) Expression of E-cadherin
in PaTu8988S, A13B and SK-PC-1 cells infected with the indicated shRNA constructs, detected by RT-qPCR. (B) Expression of E-cadherin, SNAI1 and
VIM (vimentin) in L3.6pl cells infected with the indicated constructs, measured by RT-qPCR. (C) Expression of SNAI2, ZEB1, TWIST1 and VIM in
PaTu8988S cells infected with the indicated constructs, measured by RT-qPCR. (D) GATA6 binding to the indicated regions of the E-cadherin
promoter detected by ChIP-qPCR in PaTu8988S cells. (E) Luciferase-based reporter assay showing the activity of an E-cadherin reporter in HEK293
cells transfected with empty vector (blue) or with vectors expressing either wild-type (light green) or mutated (dark green) GATA6. (F) GATA6
binding to the promoters of the indicated genes, detected by ChIP-qPCR in PaTu8988S cells. Data are presented as mean±SEM of at least three
independent experiments. *p<0.05, **p<0.01 in all panels. ChIP-qPCR data are represented as % of input normalised against a negative control
sequence, compared with binding of non-speciﬁc IgG; statistical signiﬁcance is calculated for the enrichment of GATA6 binding to the region of
interest, compared with the negative sequence.
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To further explore the relationship between GATA6 expres-
sion and patient outcome, and its predictive value, we analysed
TMAs from patients included in the ESPAC-3 trial.7 Using a his-
toscore based on the proportion of reactive cells and staining
intensity, GATA6 expression was low/undetectable in 37/313
(11.8%) tumours. GATA6 levels were associated with tumour
grade (p=0.005) but not with other clinical–pathological vari-
ables (see online supplementary table S5). Both treatment arms
were well balanced regarding patient demographics (see online
supplementary table S6). In the 5-FU/leucovorin arm, patients
with GATA6low or GATA6medium tumours survived signiﬁcantly
less than patients with GATA6high tumours (p values 0.018 and
0.039, respectively) (ﬁgure 6C). By contrast, GATA6 expression
was not associated with survival in the gemcitabine arm (ﬁgure
6D). In the univariate analysis, GATA6 levels showed a margin-
ally signiﬁcant association with outcome, exclusively among
patients receiving 5-FU/leucovorin (p=0.057) (table 2, see
online supplementary table S7). Multivariable analysis did not
reveal additional correlations (see online supplementary table
S8). Furthermore, KRT14 expression was not predictive of
outcome (see online supplementary table S7). These results
support the notion that patients with GATA6low/medium tumours
might beneﬁt less from treatment with 5-FU/leucovorin than
from treatment with gemcitabine.
We treated a panel of 11 primary cell lines established from
patient-derived xenografts (TKCC cells, see online supplemen-
tary ﬁgure S8A)35 with increasing doses of 5-FU, gemcitabine or
paclitaxel, and monitored the cytotoxic effect of the drugs.
GATA6low cells showed signiﬁcantly lower sensitivity to 1 μM
5-FU (r=−0.61, p=0.046) and a consistent tendency to lower
sensitivity to all other 5-FU concentrations (ﬁgure 7 and see
online supplementary ﬁgure S8B), while no correlation was
observed with gemcitabine or paclitaxel, regardless of the con-
centrations used (ﬁgure 7 and see online supplementary ﬁgure
S8C,D). These ﬁndings support the selective association of
GATA6 levels with 5-FU response as observed in the patients
included in ESPAC-3 trial.
To investigate whether GATA6 has a causative role in the
response to 5-FU, we knocked it down in PaTu8988S cells, as
well as in the 5-FU sensitive, GATA6high, TKCC18 and
TKCC19 cells, and we overexpressed it in L3.6pl cells and in
the 5-FU resistant, GATA6low, TKCC9, TKCC15 and TKCC26
cells. However, we did not observe signiﬁcant changes in the
sensitivity of these cells to 5-FU, gemcitabine or paclitaxel (see
online supplementary ﬁgure S9,S10, and data not shown).
DISCUSSION
An improved understanding of PDAC biology and tumour tax-
onomy should leverage on the exploitation of available therap-
ies. Here, we provide important evidence in these directions.
We extend prior data indicating GATA6 as a hallmark of
tumour differentiation, provide strong evidence that it regulates
the epithelial phenotype through novel mechanisms and show
its potential as a marker for patient stratiﬁcation.
GATA6 has a proepithelial and anti-EMT function in PDAC,
and it does so through a unique mechanism, involving both the
Figure 4 GATA6 directly activates the
proepithelial transcription factors
FOXA1 and FOXA2. (A) Representation
of ChIP-Seq peaks on FOXA1 and
FOXA2 promoters. (B) GATA6 binding
to the promoters of FOXA1 and FOXA2
detected by ChIP-qPCR in PaTu8988S
cells. (C–D) Expression of FOXA1 and
FOXA2 in L3.6 (C), PaTu8988S and
SK-PC-1 (D) cells infected with the
indicated constructs, measured by
RT-qPCR. (E) Expression of FOXA1 and
FOXA2 proteins in GATA6-silenced
PaTu8988S cells. Vinculin was used as
loading control. (F) Luciferase-based
reporter assay showing the activity of
FOXA1 and FOXA2 promoter reporters
in HEK293 cells transfected with empty
vector (blue) or with vectors expressing
either wild-type (light green) or
mutated (dark green) GATA6. In all the
panels, data are presented as mean
±SEM of at least three independent
experiments; *p<0.05, **p<0.01.
ChIP-qPCR data are represented as %
of input normalised against a negative
control sequence, compared with
binding of non-speciﬁc IgG; statistical
signiﬁcance is calculated for the
enrichment of GATA6 binding to the
region of interest, compared with the
negative sequence.
6 Martinelli P, et al. Gut 2016;0:1–12. doi:10.1136/gutjnl-2015-311256
Pancreas
group.bmj.com on June 30, 2016 - Published by http://gut.bmj.com/Downloaded from 
activation of epithelial genes and the concomitant repression of
mesenchymal genes. Furthermore, the action of GATA6 is dual:
direct—through the regulation of epithelial and mesenchymal
genes—and indirect—through the regulation of proepithelial
and promesenchymal transcription factors. To our knowledge,
GATA6 is the ﬁrst EMT regulator with such properties. GATA6
blocks dedifferentiation and the acquisition of metastatic prop-
erties in lung adenocarcinoma cells,40 but the underlying
mechanisms had not been elucidated. Here, we show that the
same is true for PDAC cells, where GATA6 downregulation
increased tumour cell dissemination. Consistently, in the
ESPAC-3 patient cohort, low GATA6 expression correlated with
moderate/poor tumour grade. Although no signiﬁcant correl-
ation was observed with lymph node status or local invasion,
the GATA6 histoscore showed a tendency to be lower in patients
that were positive for either parameter. These observations,
together with our in vitro and in vivo data, further support that
GATA6 plays a role in inhibiting tumour spreading, although
other factors appear to be involved.
Of note, GATA6-silenced PDAC cells showed reduced prolif-
eration (not shown), as previously reported,15–17 consistent with
the observation that EMT is associated with slower proliferation
Figure 5 GATA6 loss in human pancreatic ductal adenocarcinoma (PDAC) is associated with altered differentiation. (A) Expression of GATA6,
FOXA2, E-cadherin and KRT14 in two PDAC samples, detected by immunohistochemistry. Top: cells retaining GATA6 expression are FOXA2high,
E-cadherinhigh and KRT14neg; bottom: GATA6neg cells are FOXA2low, E-cadherinlow and KRT14pos. Scale bar: 50 μm. (B) Scatter plots showing
correlated expression of GATA6, FOXA2 and E-cadherin mRNA in the PDAC meta-dataset. (C) Proportion of tumours showing GATA6 ampliﬁcation
(blue) or genomic loss (red) in the combined analysis of three PDAC gene copy number variation datasets. The percentage of GATA6 losses that
were independent from loss of SMAD4 is represented in dark red.
Figure 6 GATA6 expression is
associated with outcome and with
response to adjuvant therapy. (A)
Kaplan–Meier plot of the overall
survival for patients included in the
French series. (B) Median survival of
patients included in the French series,
classiﬁed according to GATA6 level.
The value of p=0.003 calculated with
Mann–Whitney U test. (C) Kaplan–
Meier plot of the overall survival for
patients included in the 5-ﬂuorouracil
(5-FU)/leucovorin arm of the ESPAC-3
trial. (D) Kaplan–Meier plot of the
overall survival for patients included in
the gemcitabine arm of the ESPAC-3
trial.
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and reduced tumour growth.41 Proliferation was likewise
reduced in GATA6-overexpressing L3.6pl cells (not shown), sug-
gesting a more complex function for GATA6. Distinct genetic
(ie, SMAD4 status, see online supplementary table S9) and epi-
genetic landscapes might account for the discrepancy with the
previous reports.17
GATA6 also represses a basal-like transcriptional programme
similar to the one described in breast and bladder36 38 42 43 and,
more recently, in PDAC.23 Loss of canonical differentiation was
previously associated with low GATA6, both in PDAC12 and in
lung cancer.40 Furthermore, a GATA6-overexpression
signature was enriched in the classical PDAC subtype described
recently.23 However, a mechanistic explanation was completely
missing. Our work supports a causal role for GATA6 in repres-
sing this BAS-L programme in PDAC. Interestingly, a cell popu-
lation with a BAS-L phenotype is present in normal
multilayered epithelia, such as breast, bladder and lung, but not
in the single-layered pancreatic epithelium. Therefore, the emer-
gence of a basal-related programme does not necessarily reﬂect
the cell of origin of the tumour, as it was proposed, but it might
represent a common ‘low-energy’ state for multiple tumour epi-
thelial cell types. Alternatively, the BAS-L phenotype in PDAC
might represent a transition to an ectopic differentiation pro-
gramme, which could be deﬁned as an ‘epithelial-to-epithelial
transition’ (ET2). ET2 differs from the activation of lineage-
preserved ectopic differentiation programmes, such as the
gastric phenotype observed in PDAC precursors,44 also
repressed by GATA6 in mice.18 In the pancreas, the basal pro-
gramme deﬁned by the ET2 concept does not represent a devel-
opmental feature. While ET2 may herald a full-blown EMT
during tumour progression, these processes seem to be inde-
pendent in lung adenocarcinoma, where GATA6low BAS-L
tumours lack EMT features.40 More investigations are required
to assess the putative sequence from ET2 to EMT in other
tumour types and a more general role of the GATA and FOXA
protein families.
Concertedly, these ﬁndings contribute to explain the conun-
drum generated by observations supporting that GATA6 acts as
oncogene in PDAC; yet, patients with GATA6-low tumours have
worse outcome.
Sequentially regulated EMT and MET are required for efﬁ-
cient tumour spreading.45 46 GATA6 regulates both processes;
therefore, we hypothesise that the genetic context, as well as the
microenvironment, might select for loss versus gain of GATA6
expression. Multiple evidences point to context-dependent
functions: GATA6 favours EMT in vivo in Drosophila melano-
gaster and in vitro in MDCK cells47 and is required for the
tumourigenic activity of Apc loss in the mouse colon.48 The dif-
ferent outputs might depend on the levels/localisation of other
transcriptional regulators and coactivators/repressors and the
epigenetic landscape. We propose that GATA6 belongs to a new
type of cancer genes whose effect can be oncogenic or tumour-
suppressive depending on the cellular/genomic context.
GATA6 loss leads to EGFR pathway activation in PDAC cells
and in mouse PDAC,18 suggesting a predictive, or causal, role
for GATA6 in treatment response in patients. To explore this
notion, we analysed samples from patients included in ESPAC-3,
a randomised adjuvant trial comparing 5-FU/leucovorin and
gemcitabine.7 The ESPAC-3 trial showed that both treatments
had comparable effects on overall survival. We show that
patients with GATA6low tumours do not beneﬁt from adjuvant
5-FU/leucovorin and have a signiﬁcantly lower survival than
similarly treated patients with GATA6high tumours. By contrast,
GATA6 expression was not associated with the response to gem-
citabine. Altogether, these results point to GATA6 as a predictive
marker for patient stratiﬁcation. Given the antitumour activity
of FOLFIRINOX in patients with PDAC, it will be important to
determine whether GATA6 also predicts response to this drug
combination. In addition, the joint analysis of hENT and
GATA6 expression may show enhanced predictive ability.
The mechanism underlying the lack of response to
5-FU/leucovorin observed in GATA6low tumours is still to be
elucidated. The appearance of EMT features in 5-FU-resistant
cells in vitro has been reported in various solid tumours, includ-
ing PDAC,49 50 51 but a cause–effect relationship is lacking.
Modulation of GATA6 levels in TKCC cells did not change
their sensitivity to chemotherapeutic drugs, suggesting that
GATA6 is part of a molecular phenotype involved in drug
response, but it is not its major driver.
In conclusion, we provide here a thorough mechanistic ana-
lysis of GATA6 function in PDAC cells, where it inhibits
EMT, basality and dissemination, supporting its role as a
PDAC tumour suppressor, further strengthened by the
genomic losses that we and others observed, and by the
hypermethylation of GATA6 promoter described recently.52
Finally, we propose GATA6 as a valuable marker to guide
patient treatment.
Table 1 Results of the univariate analysis of survival at 3, 6, 12 and 24 months (French series)
Survival (months) Risk of mortality
3 6 12 24
Variable n n n n HR crude 95% CI p Value HR adjusted 95%CI p Value
GATA 6 (low/medium/high)
High (N=25) 25 24 16 4 1.00 1.00
Medium (N=21) 20 20 12 12 0.97 0.4 to2.6 0.943
Low (N=12) 7 5 3 3 5.39 2.3 to 12.9 <0.001 3.77 1.74 to 8.17 0.001
Table 2 Results of the univariate analysis of survival (ESPAC-3)
Risk of mortality
5-FU/leucovorin Gemcitabine Total
GATA 6 N=150 N=163 N=313
High 1.00 1.00 1.00
Medium 1.49 (1.01–2.20) 0.97 (0.67–1.39) 1.19 (0.91–1.55)
Low 1.73 (0.99–3.03) 0.99 (0.56–1.72) 1.27 (0.86–1.89)
Wald χ2 =5.72,
p=0.057
Wald χ2 =0.04,
p=0.982
Wald χ2 =2.38,
p=0.304
5-FU, 5-fluorouracil.
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METHODS
Cell lines
HEK293T and PDAC cells were cultured in DMEM supplemen-
ted with 10% FBS and NaPyr, in standard conditions (37°C,
20% O2, 5% CO2), except for L3.6pl cells, which were cultured
in RPMI with 10% serum. Mutational proﬁle of the cells used
is available in online supplementary table S9. We obtained
HEK293T cells from ATCC, A13B from C. Iacobuzio-Donahue
(Memorial Sloan Kettering, New York, USA), L3.6pl cells from
C. Heeschen (CNIO, Madrid, Spain) and PaTu8988 S from
M. Buchholz (University of Marburg, Germany). TKCC
primary cell lines were established as described.35 All remaining
PDAC cells were previously available in the laboratory.
Cytotoxicity assays
Cells were seeded at low density (5000 cells/well) in 96-well
plates and treated with either DMSO or increasing
concentrations of 5-FU (1 nM–100 μM, SIGMA-Aldrich), gem-
citabine (1 nM–100 μM, SIGMA-Aldrich) or paclitaxel
(100 pM–10 μM, SIGMA-Aldrich). After 72 hours, cells were
ﬁxed with methanol and stained with crystal violet. Crystal
violet was extracted with 1% SDS, and absorbance was mea-
sured at 595 nm.
Plasmids, transfection and infection
Lentiviral vectors expressing non-targeting and GATA6-targeting
shRNAs were purchased from SIGMA-Aldrich (MISSION
shRNA). pcDNA3 plasmids containing human wild-type and
mutated GATA6 cDNA were described earlier.17 GATA6 cDNA
was cloned into the GFP-expressing FG12 lentiviral vector for
overexpression in PDAC cells. Reporter plasmids containing
Foxa1 and Foxa2 promoters were a generous gift of Dr RJ
Matusik (Vanderbilt University, Tennessee, USA). Reporter
plasmid containing the E-cadherin promoter was a generous gift
Figure 7 GATA6 expression
negatively correlates with sensitivity to
5-ﬂuorouracil (5-FU) in pancreatic
ductal adenocarcinoma (PDAC) cells.
Scatter plots showing cell survival
upon treatment with the indicated
doses of 5-FU (top), gemcitabine
(middle) and paclitaxel (bottom),
plotted against GATA6 protein level.
Red square indicates signiﬁcant
correlation. Survival was normalised
against DMSO-treated cells. Data are
presented as the average value of at
least three independent experiments.
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of Dr A Nieto (Institute for Neurosciences, Alicante, Spain).
Virus-packaging HEK293T cells were transfected with standard
calcium phosphate protocol, supernatant was collected 48 hours
after transfection, ﬁltered and used to infect PDAC cells.
Successfully infected cells were selected either with puromycin
or by FACS-sorting.
IHC and immunoﬂuorescence
Sections were incubated with primary antibodies (see online
supplementary table S10). HRP-conjugated secondary antibodies
were from DAKO. DAB+ (3,3-diaminobenzidine tetrahy-
drochloride plus) was used as chromogen and nuclei were coun-
terstained with haematoxylin. For immunoﬂuorescence (IF)
staining, Alexa-conjugated secondary antibodies from Invitrogen
were used and nuclei were counterstained with
40-6-diamidino-2-phenylindole (DAPI). Images were pseudoco-
loured using LEICA Application Suite.
Gene expression analyses
Total RNA was extracted from cells using Trizol
(SIGMA-Aldrich) according to manufacturer’s instructions,
treated with DNase I (Ambion DNA-free kit, Invitrogen) and
converted to cDNA using TaqMan reverse transcription reagents
(Applied Biosystems). Quantitative PCR was performed using
SYBR-green mastermix (Applied Biosystems and Promega) and
run in a Prism 7900 HT instrument (Applied Biosystems).
Primers were designed using Primer3Plus, and reactions were
done in triplicate. All quantiﬁcations were normalised to
endogenous HPRT, using the standard ΔΔCt method. Primer
sequences are provided in online supplementary table S11.
Protein analysis
Protein extracts were prepared in Laemmli buffer and sonicated.
SDS–PAGE–western blotting was done using standard proto-
cols.53 Primary antibody information is provided in online sup-
plementary table S11.
Matrigel invasion assay
Transwells (BD Falcon, 0.8 μm) were coated with BD Matrigel.
Cells (105) were seeded onto Matrigel in serum-free DMEM
and were allowed to invade towards DMEM with 10% FBS.
Invading cells were ﬁxed with PFA after 24 hours (L3.6pl) or
72 hours (PaTu8988S), nuclei were stained with DAPI and
counted on a ﬂuorescent microscope. The number of invading
cells/ﬁeld was normalised by the number of cells seeded in par-
allel in a separate well.
Luciferase assay
HEK293T cells were transfected with E-cadherin, Foxa1 or
Foxa2 reporter plasmids, together with a GFP-expressing
plasmid. At the same time, empty pcDNA3 (Invitrogen), or
pcDNA3 containing either wild-type or mutant GATA6 cDNA
were introduced. Luciferase activity was measured with a lumin-
ometer, using a commercial luciferin solution (Promega) as a
substrate. Values were normalised for transfection efﬁciency by
checking GFP levels using western blotting.
ChIP
Cells were cross-linked with 1% formaldehyde for 15 min at
room temperature, harvested in lysis buffer (2×107 cells/mL)
and sonicated in a Covaris instrument (shearing time 30 min,
20% duty cycle, intensity 10, 200 cycles per burst, 30 s per
cycle) in 2 mL. ChIP was performed using anti-GATA6 R&D
AF1700 antibody, following a standard protocol.54 Independent
chromatin immunoprecipitates were used for sequencing and
for ChIP-Seq validation, using qPCR (primers are listed in
online supplementary table S7).
In vivo dissemination assay
Xenografts were performed as described.19 Brieﬂy, 5×104 cells
were resuspended in 50 μL of PBS and injected into the spleen
of athymic Foxn1nu mice; 10 weeks later, livers were explanted
and homogenised in Trizol for RNA extraction. Human-speciﬁc
HPRT primers were used to quantify the presence of human
cells. Mice were purchased from Charles River Laboratories and
maintained at CNIO under standard conditions. All experiments
were approved by the Animal Ethical Committee of Instituto de
Salud Carlos III (Madrid, Spain) and performed in accordance
with the guidelines for Ethical Conduct in the Care and Use of
Animals as stated in The International Guiding Principles for
Biomedical Research involving Animals, developed by the
Council for International Organizations of Medical Sciences
(CIOMS).
Microarray data and GSEA analyses
Hierarchical clustering of the PDAC meta-dataset was performed
with Genepattern (http://www.genepattern.broadinstitute.org).
The dataset was row-centred and column-centred, and row-
normalised and column-normalised. Differential gene expression
and GSEAwere performed with the corresponding module from
the same online suite.
Patients and samples
Detailed information is provided in the online supplementary
material.
Statistical analyses
Data are provided as mean±SEM. Statistical analysis was per-
formed using two-tailed Student’s t test or one-tailed Fisher’s
test, and signiﬁcance was considered for p<0.05. All statistical
analyses were performed using VassarStat.net and R. Detailed
information on the statistical tests used for the analysis of clin-
ical data is provided as online supplementary material.
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